Threshold Pharma (THLD) Announces TH-302 Clinical Results
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302.
As previously stated, the Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors, has completed the dose escalation component, reached the maximum tolerated dose (MTD) and is currently enrolling patients in the expansion phase of the trial at the MTD.
TH-302 continues to be tolerated and there have been no new unexpected adverse events.
The Company has two additional ongoing clinical trials of TH-302. The Company is in the process of completing a Phase 1/2 clinical trial of TH-302 in combination with various chemotherapies in patients with advanced solid tumors. The Company is also continuing a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
As previously stated, the Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors, has completed the dose escalation component, reached the maximum tolerated dose (MTD) and is currently enrolling patients in the expansion phase of the trial at the MTD.
TH-302 continues to be tolerated and there have been no new unexpected adverse events.
The Company has two additional ongoing clinical trials of TH-302. The Company is in the process of completing a Phase 1/2 clinical trial of TH-302 in combination with various chemotherapies in patients with advanced solid tumors. The Company is also continuing a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- CNH Global N.V. (CNH) Stops Doing Business with Iran
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
